insights_auto
Why is 600276 up 3.46%?
Dive Deeperchevron_right
600276:SHA
Jiangsu Hengrui Pharmaceuticals Co Ltd
CNÂ¥47.20
arrow_upward
+3.46%(+1.58) 1D
Sep 30, 3:00:00 PM GMT+8 · CNY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 600276...
Open
CNÂ¥45.60
High
CNÂ¥47.39
Low
CNÂ¥45.25
Mkt. cap
291.01B
Avg. vol.
70.64M
Volume
112.16M
Dividend
0.42%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
May 27, 2026
P/E ratio
40.51
52-wk high
CNÂ¥71.66
52-wk low
CNÂ¥41.89
EPS
CNÂ¥1.17
Shares outstanding
3.68B
No. of employees
21K
Open
CNÂ¥45.60
High
CNÂ¥47.39
Low
CNÂ¥45.25
Mkt. cap
291.01B
Avg. vol.
70.64M
Volume
112.16M
Dividend
0.42%
Quarterly dividend
CNÂ¥0.05
Ex-dividend date
May 27, 2026
P/E ratio
40.51
52-wk high
CNÂ¥71.66
52-wk low
CNÂ¥41.89
EPS
CNÂ¥1.17
Shares outstanding
3.68B
No. of employees
21K
News stories
From web sources and news partners
Yahoo Finance
·
9 hours ago
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?
Yahoo Finance
·
1 day ago
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
Investing.com
·
1 day ago
BMO reiterates Novo Nordisk stock rating on Hengrui licensing deal
Euronext Markets: Real-time Stock Market Data | live
·
1 day ago
Novo to pay up to $2.6 billion to China's Hengrui for rights to weight-loss pill
Profile
Jiangsu Hengrui Pharmaceuticals Company Ltd., also known as Jiangsu Hengrui, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials, cancer-treating antineoplastics, cardiovascular medication, painkillers, antibiotics, and related products. It is the largest listed pharmaceutical company in China. Wikipedia
About Jiangsu Hengrui Pharmaceuticals Co Ltd